Prevention of Complications (SARS-CoV-2): Clinical Study

NCT04788355 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

176

Enrollment

OTHER

Sponsor class

Conditions

Complication

Interventions

DRUG: Control group (standard hospital treatment)
DRUG: Group Hydroxychloroquine
DRUG: Group Hydroxychloroquine and apixaban
DRUG: Group Apixaban

Sponsor

Universidade do Vale do Sapucai

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]